BIORESTORATIVE THERAPIES INC (BRTX) Stock News

USA - Nasdaq - NASDAQ:BRTX - US0906556065 - Common Stock

1.05 USD

-0.03 (-2.78%)

Last: 12/4/2025, 10:15:06 AM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

BRTX Latest News, Press Relases and Analysis

All

Press Releases

14 days ago - By: Chartmill - Mentions: PBM HUSA FOSL CMCT ...

News Image

Traders are paying attention to the gapping stocks in Thursday's session.

14 days ago - By: Benzinga - Mentions: GRI PBM SCLX PACS ...

12 Health Care Stocks Moving In Thursday's Intraday Session

14 days ago - By: Benzinga - Mentions: PBM PACS ZYXI INM ...

12 Health Care Stocks Moving In Thursday's Pre-Market Session

17 days ago - By: BioRestorative Therapies, Inc

BioRestorative Granted Type B Meeting with FDA to Discuss Accelerated BLA Approval Pathway for BRTX-100 in Chronic Lumbar Disc Disease

21 days ago - By: The Motley Fool

BioRestorative (BRTX) Earnings Call Transcript

22 days ago - By: Zacks Investment Research - Mentions: TOI

Biorestorative Therapies, Inc. (BRTX) Reports Q3 Loss, Lags Revenue Estimates

24 days ago - By: Zacks Investment Research - Mentions: CRSP

CRISPR Therapeutics AG (CRSP) Reports Q3 Loss, Lags Revenue Estimates

a month ago - By: BioRestorative Therapies, Inc

BioRestorative Therapies to Report Third Quarter 2025 Financial Results and Host Conference Call on November 12, 2025

a month ago - By: BioRestorative Therapies, Inc

BioRestorative Awarded Notice of Allowance for Japanese Patent – Expands Protection for Potential Cell-Based Alternative to Multi-Billion Dollar GLP-1 Drug Market

a month ago - By: BioRestorative Therapies, Inc

BioRestorative Strengthens Commercial Leadership with Appointment of Crystal Romano as Head of Global Commercial Operations to Accelerate Growth of Cell-Based Product Portfolio

2 months ago - By: BioRestorative Therapies, Inc

BioRestorative Therapies to Participate in the 2025 Maxim Growth Summit

2 months ago - By: Zacks Investment Research

Is Bayer (BAYRY) Outperforming Other Medical Stocks This Year?

2 months ago - By: BioRestorative Therapies, Inc

BioRestorative CEO Lance Alstodt Interviewed on “The Big Biz Show”

2 months ago - By: BioRestorative Therapies, Inc

BioRestorative Therapies Announces $1.085 Million Registered Direct Offering Priced Above Market

4 months ago - By: Zacks Investment Research - Mentions: BDTX

Are Medical Stocks Lagging Black Diamond Therapeutics (BDTX) This Year?

4 months ago - By: Zacks Investment Research

Biorestorative Therapies, Inc. (BRTX) Reports Q2 Loss, Beats Revenue Estimates

4 months ago - By: Zacks Investment Research - Mentions: ZYME

Zymeworks Inc. (ZYME) Tops Q2 Earnings and Revenue Estimates

4 months ago - By: Zacks Investment Research - Mentions: TRDA

Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Lags Revenue Estimates

4 months ago - By: BioRestorative Therapies, Inc

BioRestorative Therapies to Report Second Quarter 2025 Financial Results and Host Conference Call on August 12, 2025

6 months ago - By: BioRestorative Therapies, Inc

BioRestorative to Participate in Benzinga All-Access Show Today to Discuss Compelling BRTX-100 Clinical Data, Leadership Enhancements and Strategic updates

6 months ago - By: BioRestorative Therapies, Inc

BioRestorative Announces Share Repurchase Program

6 months ago - By: BioRestorative Therapies, Inc

BioRestorative Reports Compelling Preliminary Data for FDA-Fast-Tracked BRTX-100 – an Autologous Stem Cell Therapy to Treat Chronic Lumbar Disc Disease

6 months ago - By: BioRestorative Therapies, Inc

BioRestorative Welcomes Serial Regenerative Medicine Entrepreneur, Company Builder and Leader, Sandy Lipkins, to BRTX Team

6 months ago - By: BioRestorative Therapies, Inc

BioRestorative to Present Major Update on Promising Preliminary Phase 2 BRTX-100 Data at ISSCR 2025

7 months ago - By: Zacks Investment Research - Mentions: CGEN

Biorestorative Therapies, Inc. (BRTX) Reports Q1 Loss, Lags Revenue Estimates

7 months ago - By: Zacks Investment Research - Mentions: STOK

Stoke Therapeutics, Inc. (STOK) Tops Q1 Earnings and Revenue Estimates

7 months ago - By: BioRestorative Therapies, Inc

Phase 2 Trial of BRTX-100 in cLDD Continues to Generate Positive Preliminary Blinded Data

7 months ago - By: Zacks Investment Research - Mentions: CHRS

Coherus BioSciences (CHRS) Reports Q1 Loss, Lags Revenue Estimates